8i Acquisition 2 Corp.
LAXXW
NASDAQ Global Market0.20
USD
-0.14
- -
CIK
0001847846
Return %
Stock
S&P500
1Y
-59.67
26.84
3Y
-59.67
77.03
5Y
-59.67
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001847846
- Similar Companies
- Business
- 8i Acquisition 2 Corp. 8i Acquisition 2 Corp. (NASDAQ:LAXXW) operates as a blank check company, or special purpose acquisition company (SPAC), incorporated in the British Virgin Islands in January 2021 and headquartered in Singapore, with the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities, focusing primarily on targets in Asia across various industries including industrials, tourism, and healthcare; it generates no significant independent operations or revenue prior to completing an initial business combination and holds cash proceeds from its November 2021 initial public offering in trust for deployment post-combination. The company offered units comprising ordinary shares, warrants, and rights in its IPO, raising approximately $86.3 million before redemptions, with warrants (traded as LAXXW) exercisable into ordinary shares upon a successful business combination and rights entitling holders to a fraction of an ordinary share thereunder; securities commenced separate trading in December 2021. In a major development, 8i Acquisition 2 Corp. completed a business combination with EUDA Health Limited, a Singapore-based digital health platform, in November 2022 via a share purchase agreement, resulting in the combined entity operating as EUDA Health Holdings Limited (NASDAQ: EUDA), which provides AI-driven personalized healthcare services, telemedicine platforms, and patient outcome solutions across Southeast Asia including Singapore, Malaysia, Indonesia, and India; the transaction, initially valued at an enterprise value of $583 million but amended downward to $172 million amid market conditions and revised projections, delivered approximately $86 million in trust proceeds (net of redemptions) for EUDA's product development, AI research, geographic expansion, and strategic investments, with earnouts of up to 13 million shares tied to post-close share price milestones. Subsequent to the merger, EUDA Health Holdings Limited has navigated Nasdaq compliance challenges, including bid price deficiencies noted in 2023 and market value issues addressed by early 2024, while undergoing strategic shifts such as closing underperforming medical clinics in September 2023 amid post-COVID demand weakness to streamline operations and pivot toward wellness services; recent initiatives include the acquisition of CK Health Plus Pte. Ltd., expansion into India through a October 2025 partnership with SafeRock India Pvt. Ltd. for distributing Bioenergy Capsule Therapies and EUDA Helixé supplements via network marketing in cities like Mumbai and Bangalore, and securing a Malaysian Direct Selling License (AJL 932509) for CK Health Plus in October 2025 to bolster regional wellness ecosystem growth. As of late 2025, LAXXW warrants remain actively traded components of the original SPAC structure, reflecting ongoing market interest in potential exercise value tied to EUDA Health Holdings Limited's performance in the digital health and wellness sectors.